Dr. Letai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Avenue
Dana Farber Cancer Institute
Boston, MA 02215Phone+1 617-632-2348Fax+1 617-632-5168- Is this information wrong?
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2001
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1995
Certifications & Licensure
- MA State Medical License 1997 - 2026
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Member Association of American Physicians, 2018
- Elected Member The American Society for Clinical Investigation, 2009
Publications & Presentations
PubMed
- 118 citationsBH3 profiling in whole cells by fluorimeter or FACSJeremy Ryan, Anthony Letai
Methods. 2013-06-01 - 445 citationsPretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic ChemotherapyTriona Ni Chonghaile, Kristopher A. Sarosiek, Thanh Trang T. Vo, Jeremy Ryan, Anupama Tammareddi
Science. 2011-11-25 - 113 citationsAlteration of the Mitochondrial Apoptotic Pathway Is Key to Acquired Paclitaxel Resistance and Can Be Reversed by ABT-737Ozgur Kutuk, Anthony Letai
Cancer Research. 2008-10-01
Journal Articles
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D Dinardo, Brian A Jonas, Jacqueline S Garcia, Anthony Letai, Wan-Jen Hong, Keith W Pratz, The New England Journal of Medicine
- Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid LeukemiaBrian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
- Targeted Inhibition of PI3Kα/Δ Is Synergistic with BCL-2 Blockade in Genetically Defined Subtypes of DLBCLAnthony Letai, Margaret A Shipp, Blood
- Join now to see all
Abstracts/Posters
- MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid CancersAnthony G. Letai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLLAnthony G. Letai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic LeukemiaAnthony G. Letai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Authored Content
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaAugust 2020
- Join now to see all
Press Mentions
- Science Researchers Demonstrate How Novel Drug Screen Can Individualise Cancer TherapyJune 12th, 2021
- Study Shows How Novel Drug Screen Can Individualise Cancer TherapyJune 9th, 2021
- Cancer Response to Drugs Predicted Through New Screening MethodJune 17th, 2020
- Join now to see all
Hospital Affiliations
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: